Accord Healthcare Us

Accord Healthcare Us company information, Employees & Contact Information

Updated June 2026

Quick answer

Accord Healthcare Us is a Pharmaceutical Manufacturing company. It has approximately 32 employees on record. Contact data was last refreshed in June 2026. Find Accord Healthcare Us's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Accord Healthcare is a large-scale provider of generic pharmaceuticals in the United States. Our U.S. headquarters is in Durham, North Carolina, near the Research Triangle Park (RTP). Situated in a 7,000-acre pine forest, RTP is one of the largest research parks in the world. Close to three major research universities, the area provides an unparalleled scientific, regulatory, quality, and commercial talent pool. Accord is the commercial arm of Intas Pharmaceuticals, a pioneering biopharmaceutical company operating in India since 1976. Selling in over 75 countries, Accord has a vast global presence. The Accord and Intas networks provide full integration in the functional areas vital to delivering quality excellence and service efficiencies: API and finished dosage form manufacturing, R & D, clinical program management, and the economies of scale inherent in worldwide distribution. Accord is routinely cited in IQVIA presentations to industry as one of the fastest growing pharmaceutical companies in the U.S. Quarter-over-quarter, we consistently accomplish double-digit growth across all the metrics: in dollar sales, scripts filled, and number of units sold. We have accomplished this while undergoing multiple plant expansions across all of our manufacturing sites. Our solid record of maintaining high quality standards while implementing strategic commercial expansion has set us apart in the industry. Accord’s product offerings and pipeline demonstrate our commitment to meeting the needs of healthcare professionals and patients alike. We currently have approval for more than 115 ANDAs and are selling over 290 dosing presentations. We have 52 ANDAs pending at the FDA, and over 115 products in active development. Our pipeline spans a full range of dosage forms: orals, topicals, transdermal patches, liquid, lyophilized and complex injectables.

Company Details

Employees
32
Address
1009 Slater Road,
Phone
(919)941-7879
Email
us****@****are.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Durham, NC
Looking for a particular Accord Healthcare Us employee's phone or email?

Accord Healthcare Us Questions

News

Accord Healthcare Launches Dehydrated Alcohol Injection for Cardiovascular Indications - PR Newswire

Accord Healthcare Launches Dehydrated Alcohol Injection for Cardiovascular Indications PR Newswire

The FDA Let Substandard Factories Ship These Medications to the U.S. - ProPublica

The FDA Let Substandard Factories Ship These Medications to the U.S. ProPublica

Intas & Accord signs Agreement to acquire Prothya Biosolutions - PR Newswire

Intas & Accord signs Agreement to acquire Prothya Biosolutions PR Newswire

Generic Product News: August 2022 - Pharmacy Times

Generic Product News: August 2022 Pharmacy Times

Patent case: Novartis Pharmaceuticals Corporation. v. Accord Healthcare, Inc., USA - Wolters Kluwer

Patent case: Novartis Pharmaceuticals Corporation. v. Accord Healthcare, Inc., USA Wolters Kluwer

Amid shortage, Accord Healthcare restarts production of cancer drug cisplatin - Fierce Pharma

Amid shortage, Accord Healthcare restarts production of cancer drug cisplatin Fierce Pharma

Accord Healthcare Launches Generic Drug For Treating Brain Tumors & Blood Cancers - citybiz

Accord Healthcare Launches Generic Drug For Treating Brain Tumors & Blood Cancers citybiz

Accord Healthcare Inc. Announces Launch of First-to-Market Additional Strengths of Hydroxychloroquine Sulfate Tablets, in the U.S. - BioSpace

Accord Healthcare Inc. Announces Launch of First-to-Market Additional Strengths of Hydroxychloroquine Sulfate Tablets, in the U.S. BioSpace

Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq® - PR Newswire

Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq® PR Newswire

Accord Healthcare to build £50m medicines manufacturing facility in Newcastle, creating 50+ jobs - The Manufacturer

Accord Healthcare to build £50m medicines manufacturing facility in Newcastle, creating 50+ jobs The Manufacturer

Drugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can’t Get Meds - KFF Health News

Drugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can’t Get Meds KFF Health News

Accord Healthcare Inc - Pharmacy Times

Accord Healthcare Inc Pharmacy Times

Accord Healthcare Releases Generic Drug Proven Effective Against Vitamin B12 Deficiency - PR Newswire

Accord Healthcare Releases Generic Drug Proven Effective Against Vitamin B12 Deficiency PR Newswire

Accord Healthcare Offers Generic Option for Treatment of Schizophrenia and Bipolar Depression - PR Newswire

Accord Healthcare Offers Generic Option for Treatment of Schizophrenia and Bipolar Depression PR Newswire

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio - PR Newswire

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio PR Newswire

Accord Healthcare Releases Generic Drug Proven Effective in Treating Major Depressive Disorder in Adults - PR Newswire

Accord Healthcare Releases Generic Drug Proven Effective in Treating Major Depressive Disorder in Adults PR Newswire

Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - PR Newswire

Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth PR Newswire

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara® - PR Newswire

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara® PR Newswire

Accord Healthcare’s Tacrolimus Oral Capsules No Longer Substitutable for Prograf - Medical Professionals Reference

Accord Healthcare’s Tacrolimus Oral Capsules No Longer Substitutable for Prograf Medical Professionals Reference

Esperion settles litigation with Accord Healthcare (ESPR) - Seeking Alpha

Esperion settles litigation with Accord Healthcare (ESPR) Seeking Alpha

How troubles at a factory in India led to a U.S. cancer-drug shortage - The Washington Post

How troubles at a factory in India led to a U.S. cancer-drug shortage The Washington Post

US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Business Wire

US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® Business Wire

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, ustekinumab biosimilar to Stelara® - Business Standard

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, ustekinumab biosimilar to Stelara® Business Standard

New hires at Bayer, Eisai and Accord Healthcare - PMLiVE

New hires at Bayer, Eisai and Accord Healthcare PMLiVE

Anthony Grosso new head of scientific affairs at Accord Healthcare - PharmaTimes

Anthony Grosso new head of scientific affairs at Accord Healthcare PharmaTimes

Accord Healthcare resumes production of cancer drug cisplatin amid shortages - ET HealthWorld

Accord Healthcare resumes production of cancer drug cisplatin amid shortages ET HealthWorld

Peter Kelly named managing director of Accord Healthcare UK - PMLiVE

Peter Kelly named managing director of Accord Healthcare UK PMLiVE

Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe - Pinsent Masons

Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe Pinsent Masons

Accord Healthcare Ireland appoints Padraic O’Brien as Managing Director - Irish Medical Times

Accord Healthcare Ireland appoints Padraic O’Brien as Managing Director Irish Medical Times

Top Accord Healthcare Us Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant